Cargando…

Molecular Markers for Bladder Cancer Screening: An Insight into Bladder Cancer and FDA-Approved Biomarkers

Bladder cancer is one of the most financially burdensome cancers globally, from its diagnostic to its terminal stages. The impact it imposes on patients and the medical community is substantial, exacerbated by the absence of disease-specific characteristics and limited disease-free spans. Frequent r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flores Monar, Gabriela Vanessa, Reynolds, Thomas, Gordon, Maxie, Moon, David, Moon, Chulso
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10531979/ https://www.ncbi.nlm.nih.gov/pubmed/37762677 http://dx.doi.org/10.3390/ijms241814374

Ejemplares similares

Development of Multiplex Polymerase Chain Reaction (PCR)-Based MSA Assay for Bladder Cancer Detection
por: Reynolds, Thomas, et al.
Publicado: (2023)

Microsatellite Instability Analysis (MSA) for Bladder Cancer: Past History and Future Directions
por: Moon, Chulso, et al.
Publicado: (2021)

An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
por: Tong, Juliana T. W., et al.
Publicado: (2021)

Epigenetic silencing of S100A2 in bladder and head and neck cancers
por: Lee, Juna, et al.
Publicado: (2015)

Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
por: Füzéry, Anna K, et al.
Publicado: (2013)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

FDA-approved immunosuppressants targeting staphylococcal superantigens: mechanisms and insights
por: Krakauer, Teresa
Publicado: (2017)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Identification of FDA-approved Drugs Targeting Breast Cancer Stem Cells Along With Biomarkers of Sensitivity
por: Bhat-Nakshatri, Poornima, et al.
Publicado: (2013)

FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients
por: Wang, Ye, et al.
Publicado: (2021)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Post-translational modifications of FDA-approved plasma biomarkers in glioblastoma samples
por: Petushkova, Natalia A., et al.
Publicado: (2017)

Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000–2020)
por: Kim, Jeeyun A., et al.
Publicado: (2021)

Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection
por: Wang, Shaobo, et al.
Publicado: (2017)

Screening of an FDA-Approved Library for Novel Drugs against Y. pestis
por: Gur, David, et al.
Publicado: (2021)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Urinary markers for bladder cancer
por: Smith, Zachary L., et al.
Publicado: (2013)

Molecular markers in bladder cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Computational Insights and Virtual Screening of Repurposed FDA-Approved Drug Against SARS-CoV-2 Protease
por: Joel, C., et al.
Publicado: (2023)

Plasma preparation to measure FDA-approved protein markers by selected reaction monitoring
por: Kiseleva, Olga I., et al.
Publicado: (2015)

Parallel screening of FDA-approved antineoplastic drugs for identifying sensitizers of TRAIL-induced apoptosis in cancer cells
por: Taylor, David J, et al.
Publicado: (2011)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
por: Twomey, Julianne D., et al.
Publicado: (2021)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

The Performance of FDA-Approved PET Imaging Agents in the Detection of Prostate Cancer
por: Li, Mei, et al.
Publicado: (2022)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
por: Chaurasia, Mohini, et al.
Publicado: (2023)

Circulating Biomarkers in Bladder Cancer
por: Nandagopal, Lakshminarayanan, et al.
Publicado: (2016)

Biomarkers in Bladder Cancer Surveillance
por: Sugeeta, Sukumar S., et al.
Publicado: (2021)

A Systematic Screen of FDA-Approved Drugs for Inhibitors of Biological Threat Agents
por: Madrid, Peter B., et al.
Publicado: (2013)

FDA Approved Drug Library Screening Identifies Robenidine as a Repositionable Antifungal
por: Mei, Yikun, et al.
Publicado: (2020)

Network model‐based screen for FDA‐approved drugs affecting cardiac fibrosis
por: Zeigler, Angela C., et al.
Publicado: (2021)

Virtual Screening of FDA-Approved Drugs for Enhanced Binding with Mitochondrial Aldehyde Dehydrogenase
por: Zhou, Boqian, et al.
Publicado: (2022)

Screening of an FDA-approved compound library identifies apigenin for the treatment of myocardial injury
por: Li, Haixia, et al.
Publicado: (2023)

Aquaporin 5 (AQP5) expression in breast cancer and its clinicopathological characteristics
por: Jang, Se Jin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_aacprdb53c6pn9rjk6po3qjq3n